Insider Buying: GSK (LON:GSK) Insider Acquires 7 Shares of Stock

Key Points

• GSK insider Julie Brown bought 7 shares at GBX 1,803 each, for a total investment of £126.21.
• GSK shares fell 0.3% to GBX 1,770.50, with the company valued at approximately £70.94 billion.
• Analysts maintain a consensus “Hold” rating with an average price target of GBX 2,039.38; ratings include two Buys, five Holds, and one Sell.

GSK plc (LON:GSK - Get Free Report) insider Julie Brown bought 7 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were acquired at an average cost of GBX 1,803 per share, for a total transaction of £126.21.

GSK Stock Down 0.3%

Shares of GSK traded down GBX 5 during trading hours on Friday, hitting GBX 1,770.50. The company had a trading volume of 922,420,813 shares, compared to its average volume of 13,290,600. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. The company has a market capitalization of £70.94 billion, a PE ratio of 15.03, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. GSK plc has a one year low of GBX 1,455 and a one year high of GBX 2,282. The company's fifty day moving average price is GBX 1,906.66 and its two-hundred day moving average price is GBX 1,969.53.

GSK (LON:GSK - Get Free Report) last announced its earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. As a group, equities analysts forecast that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on GSK. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a GBX 2,000 price target on shares of GSK in a research note on Wednesday, September 2nd. Royal Bank Of Canada reiterated a "sector perform" rating and issued a GBX 1,975 target price on shares of GSK in a research note on Tuesday. Finally, Jefferies Financial Group reissued a "buy" rating and set a GBX 2,500 target price on shares of GSK in a research report on Wednesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of GBX 2,039.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.